BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

53 related articles for article (PubMed ID: 38715141)

  • 1. CircHIF1A induces cetuximab resistance in colorectal cancer by promoting HIF1α-mediated glycometabolism alteration.
    Geng Y; Zheng X; Zhang D; Wei S; Feng J; Wang W; Zhang L; Wu C; Hu W
    Biol Direct; 2024 May; 19(1):36. PubMed ID: 38715141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of CircRNA/miRNA/mRNA axis in breast cancer drug resistance.
    Ghazimoradi MH; Babashah S
    Front Oncol; 2022; 12():966083. PubMed ID: 36132137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Promotion or remission: a role of noncoding RNAs in colorectal cancer resistance to anti-EGFR therapy.
    Wei S; Hu W; Feng J; Geng Y
    Cell Commun Signal; 2022 Sep; 20(1):150. PubMed ID: 36131281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N
    Zhang K; Zhang T; Yang Y; Tu W; Huang H; Wang Y; Chen Y; Pan K; Chen Z
    Theranostics; 2022; 12(10):4802-4817. PubMed ID: 35832094
    [No Abstract]   [Full Text] [Related]  

  • 5. Nanodrugs Incorporating LDHA siRNA Inhibit M2-like Polarization of TAMs and Amplify Autophagy to Assist Oxaliplatin Chemotherapy against Colorectal Cancer.
    Hu L; Huang S; Chen G; Li B; Li T; Lin M; Huang Y; Xiao Z; Shuai X; Su Z
    ACS Appl Mater Interfaces; 2022 Jul; 14(28):31625-31633. PubMed ID: 35796429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. circRNA_101277 Influences Cisplatin Resistance of Colorectal Cancer Cells by Modulating the miR-370/IL-6 Axis.
    Lv Q; Xia Q; Li A; Wang Z
    Genet Res (Camb); 2022; 2022():4237327. PubMed ID: 35356749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer statistics in China and United States, 2022: profiles, trends, and determinants.
    Xia C; Dong X; Li H; Cao M; Sun D; He S; Yang F; Yan X; Zhang S; Li N; Chen W
    Chin Med J (Engl); 2022 Feb; 135(5):584-590. PubMed ID: 35143424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor-derived exosomal circRNA_102481 contributes to EGFR-TKIs resistance via the miR-30a-5p/ROR1 axis in non-small cell lung cancer.
    Yang B; Teng F; Chang L; Wang J; Liu DL; Cui YS; Li GH
    Aging (Albany NY); 2021 May; 13(9):13264-13286. PubMed ID: 33952725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
    Sung H; Ferlay J; Siegel RL; Laversanne M; Soerjomataram I; Jemal A; Bray F
    CA Cancer J Clin; 2021 May; 71(3):209-249. PubMed ID: 33538338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CircRNA_0000392 promotes colorectal cancer progression through the miR-193a-5p/PIK3R3/AKT axis.
    Xu H; Liu Y; Cheng P; Wang C; Liu Y; Zhou W; Xu Y; Ji G
    J Exp Clin Cancer Res; 2020 Dec; 39(1):283. PubMed ID: 33317596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial.
    Heinemann V; von Weikersthal LF; Decker T; Kiani A; Kaiser F; Al-Batran SE; Heintges T; Lerchenmüller C; Kahl C; Seipelt G; Kullmann F; Moehler M; Scheithauer W; Held S; Miller-Phillips L; Modest DP; Jung A; Kirchner T; Stintzing S
    Br J Cancer; 2021 Feb; 124(3):587-594. PubMed ID: 33154570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CircRNA CDR1as/miR-641/HOXA9 pathway regulated stemness contributes to cisplatin resistance in non-small cell lung cancer (NSCLC).
    Zhao Y; Zheng R; Chen J; Ning D
    Cancer Cell Int; 2020; 20():289. PubMed ID: 32655321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circular RNAs in the tumour microenvironment.
    Ma Z; Shuai Y; Gao X; Wen X; Ji J
    Mol Cancer; 2020 Jan; 19(1):8. PubMed ID: 31937318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytoreduction for colorectal metastases: liver, lung, peritoneum, lymph nodes, bone, brain. When does it palliate, prolong survival, and potentially cure?
    Stewart CL; Warner S; Ito K; Raoof M; Wu GX; Kessler J; Kim JY; Fong Y
    Curr Probl Surg; 2018 Sep; 55(9):330-379. PubMed ID: 30526930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients With
    Qin S; Li J; Wang L; Xu J; Cheng Y; Bai Y; Li W; Xu N; Lin LZ; Wu Q; Li Y; Yang J; Pan H; Ouyang X; Qiu W; Wu K; Xiong J; Dai G; Liang H; Hu C; Zhang J; Tao M; Yao Q; Wang J; Chen J; Eggleton SP; Liu T
    J Clin Oncol; 2018 Oct; 36(30):3031-3039. PubMed ID: 30199311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of HK2, PKM2 and LDHA on Cetuximab efficacy in metastatic colorectal cancer.
    Wang H; Peng R; Chen X; Jia R; Huang C; Huang Y; Xia L; Guo G
    Oncol Lett; 2018 Apr; 15(4):5553-5560. PubMed ID: 29552193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CircHIPK3 promotes colorectal cancer growth and metastasis by sponging miR-7.
    Zeng K; Chen X; Xu M; Liu X; Hu X; Xu T; Sun H; Pan Y; He B; Wang S
    Cell Death Dis; 2018 Apr; 9(4):417. PubMed ID: 29549306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Silencing of hsa_circ_0007534 suppresses proliferation and induces apoptosis in colorectal cancer cells.
    Zhang R; Xu J; Zhao J; Wang X
    Eur Rev Med Pharmacol Sci; 2018 Jan; 22(1):118-126. PubMed ID: 29364478
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.